Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04576156 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04576156 · ClinicalTrials.gov record · last posted 2026-07-08

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

StatusActive, Not Recruiting
PhasePhase 3
Started2021-04-12
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.

Amendment record 64 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 64 times since 2020-10-02; most recent amendment 2026-07-06. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-10-24
Status change Recruiting→Active, Not Recruitingv61
2020-12-23
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT04576156
Lead Sponsor Geron Corporation
Conditions Myelofibrosis
Enrollment 327 participants
Start Date 2021-04-12
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-08